Biotech and neurodegeneration readers will find an illuminating profile of a startup pursuing a brain-targeted Parkinson's therapy, its recent funding and scientific roadmap.
Key Takeaways
- Reducing mTOR activity activates autophagy, helping clear alpha-synuclein implicated in Parkinson's disease
- Systemic mTOR inhibition can cause immune suppression, impaired wound healing and metabolic complications
- Montara will test mTOR inhibitors with its peripheral blocker in models to prioritize safe candidates